TY - JOUR
T1 - What have we learned from basic science studies on idiopathic pulmonary fibrosis?
AU - Yanagihara, Toyoshi
AU - Sato, Seidai
AU - Upagupta, Chandak
AU - Kolb, Martin
N1 - Funding Information:
Support statement: This study was funded by the Canadian Institutes of Health Research, Institute of Circulatory and Respiratory Health (MOP136950). Funding information for this article has been deposited with the Crossref Funder Registry.
Funding Information:
Conflict of interest: T. Yanagihara reports personal fees from Prometic, outside the submitted work. S. Sato reports grants from Canadian Institute for Health Research, during the conduct of the study. C. Upagupta reports grants from Canadian Institute for Health Research, during the conduct of the study. M. Kolb reports grants from Canadian Institute for Health Research, during the conduct of the study; grants and personal fees from Roche, Boehringer Ingelheim and Prometic, grants from Actelion, Respivert and Alkermes, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work.
Funding Information:
Provenance: Publication of this peer-reviewed article was sponsored by Boehringer Ingelheim, Germany sponsor European Respiratory Review issue 153).
Publisher Copyright:
© ERS 2019.
PY - 2019/9/30
Y1 - 2019/9/30
N2 - Idiopathic pulmonary fibrosis is a fatal age-related lung disease characterised by progressive and irreversible scarring of the lung. Although the details are not fully understood, there has been tremendous progress in understanding the pathogenesis of idiopathic pulmonary fibrosis, which has led to the identification of many new potential therapeutic targets. In this review we discuss several of these advances with a focus on genetic susceptibility and cellular senescence primarily affecting epithelial cells, activation of profibrotic pathways, disease-enhancing fibrogenic cell types and the role of the remodelled extracellular matrix.
AB - Idiopathic pulmonary fibrosis is a fatal age-related lung disease characterised by progressive and irreversible scarring of the lung. Although the details are not fully understood, there has been tremendous progress in understanding the pathogenesis of idiopathic pulmonary fibrosis, which has led to the identification of many new potential therapeutic targets. In this review we discuss several of these advances with a focus on genetic susceptibility and cellular senescence primarily affecting epithelial cells, activation of profibrotic pathways, disease-enhancing fibrogenic cell types and the role of the remodelled extracellular matrix.
UR - http://www.scopus.com/inward/record.url?scp=85072111966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072111966&partnerID=8YFLogxK
U2 - 10.1183/16000617.0029-2019
DO - 10.1183/16000617.0029-2019
M3 - Review article
C2 - 31511255
AN - SCOPUS:85072111966
SN - 0905-9180
VL - 28
JO - European Respiratory Review
JF - European Respiratory Review
IS - 153
M1 - 190029
ER -